Evidence map›Paper›PMID 41671740›Full record

ArticleBioorganic chemistry2026

An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition.

Xiuqi Wang, Rosa Anna DeFilippis, Huimin Geng, Neil P Shah, Hong-Yu Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiuqi WangDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Rosa Anna DeFilippisDivision of Hematology/Oncology, University of California, San Francisco, CA, USA.
Huimin GengDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Neil P ShahDivision of Hematology/Oncology, University of California, San Francisco, CA, USA.
Hong-Yu LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pharmacology, The Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Funding

Impact of myeloid leukemia associated mutations (ASXL1, DNMT3A, TET2, IDH1 and IDH2) on treatment responses among Chronic Myeloid Leukemia (CML) patients in TanzaniaR01CA249282 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LI, HONG-YU, SHAH, NEIL P · 2021 to 2025
$3.4M
NCI NIH HHS R01 CA249282
6 · The paper itself

Abstract

Activating mutations in FLT3 occur in 30% of acute myeloid leukemia (AML) cases. The AML patient-derived MV4-11 cell line contains a genetic alteration in FLT3 ("FLT3-ITD"), causing constitutive FLT3 activation. From screening, we identified compound 1 with unprecedently high anti-MV4-11 effects, with IC

Indexed as

Antineoplastic Agentsfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansLeukemia, Myeloid, AcuteMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsAcute myeloid leukemiaFLT3mv4–11

Identifiers

PMID41671740
PMCPMC13178952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.